VSports app下载 - Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Editorial
. 2011 Mar;96(3):347-9.
doi: 10.3324/haematol.2010.039560.

V体育安卓版 - Mutant BCR-ABL clones in chronic myeloid leukemia

Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Elias Jabbour
Editorial

VSports app下载 - Mutant BCR-ABL clones in chronic myeloid leukemia

Michael S Mathisen et al. Haematologica. 2011 Mar.
No abstract available

PubMed Disclaimer

VSports注册入口 - Comment on

References

    1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–7. - PubMed
    1. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–61. - V体育官网 - PubMed
    1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17. - PubMed
    1. Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) Blood. 2009;114:462. abstract 1126.
    1. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol. 2007;8(11):1018–29. - PubMed

MeSH terms

Substances